Japan Drug Approvals | Healthcare

UCB’s Epilepsy Drug Briviact (brivaracetam) Gains Approval in Japan for Focal Onset Seizures | 2024 | iPharmaCenter

Briviact (brivaracetam) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) as both a monotherapy and...

Takeda Announces Approval of Livtencity in Japan for Resistant Post-Transplant Cytomegalovirus (CMV) Infection/Disease

Takeda announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Livtencity (maribavir) for the...

Dupixent approved for chronic spontaneous urticaria Japan became the first country to approve Dupixent for chronic spontaneous urticaria...

Japan Drug Approvals | 2023 | MHLW | PMDA | iPharmaCenter

Bimzelx was approved in Japan for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis Bimzelx...

Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System

Mar 12. 2021 Takeda’s New Drug Application was submitted for MHLW in Japan for Hereditary Angioedema Attacks Takeda announced that it...

Lynparza was approved for three more indications in Japan

AstraZeneca and Merck announced that Lynparza (olaparib) was approved for three more indications in Japan. The three new cancer...

Merck’s Keytruda received one more indication and dosage form approval in Japan

Merck has announced that it has received the approval of its anti-PD-1 therapy, Keytruda (pembrolizumab) for radically unresectable,...

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

Gilead has announced top-line Phase 3 trial results of remdesivir in patients with COVID-19. The drug is indicated in moderate COVID-19...

Astellas received approval for Xtandi in Japan for prostate cancer

Astellas announced that it had received approval from Japan Ministry of Health, Labour and Welfare (MHLW) for Xtandi (enzalutamide) for...